Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-29T18:43:48.240Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing the impact of Tadalafil on the sexuality and quality of life after acute urinary retention: a randomized controlled Trial

Published online by Cambridge University Press:  19 July 2023

K. Bouassida ,
A. Loghmari ,
M. Ben Othmen ,
G. Tlili ,
E. Acacha ,
W. Ben Abdallah ,
M. Kahloul ,
W. Hmida ,
R. Jaballah  and
A. Zorgati
...Show all authors
K. Bouassida
Affiliation:
Urology
A. Loghmari*
Affiliation:
Urology
M. Ben Othmen
Affiliation:
Urology
G. Tlili
Affiliation:
Urology
E. Acacha
Affiliation:
Urology
W. Ben Abdallah
Affiliation:
Urology
M. Kahloul
Affiliation:
Anesthesiology department
W. Hmida
Affiliation:
Urology
R. Jaballah
Affiliation:
Emergency Department, Sahloul teachin Hospital Sousse, Sousse, Tunisia
A. Zorgati
Affiliation:
Emergency Department, Sahloul teachin Hospital Sousse, Sousse, Tunisia
R. Boufek
Affiliation:
Emergency Department, Sahloul teachin Hospital Sousse, Sousse, Tunisia
M. Jaidane
Affiliation:
Urology
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Acute urinary retention (AUR) is known to have major impact on the quality of life and sexuality of patients with benign prostatic hyperplasia (BPH). However, little is known about specific approachs that could reduce this impact. Tadalafil, an efficient medication in uncomplicated BPH, may be also useful in serious complications, especially the AUR.

Objectives

The aim of this study is to assess the impact of Tadalafil on sexuality and quality of life in patients AUR related to BPH.

Methods

This is a randomized, double-blind clinical trial conducted in the Urology and Emergency Departments of Sahloul Teaching Hospital, between June 2020 and January 2022. Consenting men over the age of 45 who had an AUR complicating a BPH were included. Fifty three patients were enrolled and randomized into two groups: intervention group (n=29) in which patients received 5 mg/day of Tadalafil, and control group (n=24) in which patients received a comparable tablet of placebo. The evaluation focused on sexuality and quality of life. For theses purposes we used SF-36 short form and IIEF 15.

Results

Socio-demographic characteristics were comparable between both groups. Sexuality assessed by IIEF 15 was significantly better in the intervention group (p=0.02). The four SF-36 domains were also significantly improved by Tadalafil: “Physical Function” (p=0.046), “Pain” (p=0.01), “General Health” (p=0.029) and “Health change” (p=0.02).

Conclusions

Sexuality and quality of life could be improved by Tadalafil in complicated BPH.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1094
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.